Table 4.
Multivariable analysis for clinical outcome for patienets with AML(RFS).
| Relapse-free survival |
||
| Variables | P-value | HR (95%CI) |
| MAP4K1 expression (High vs Low) | 0.005 | 2.369(1.302,4.311) |
| Age | 0.007 | 1.034(1.009,1.058) |
| WBC | 0.370 | 1.003(0.997,1.008) |
| BM blast | 0.023 | 1.017(1.002,1.031) |
| Karyotype-risk group | ||
| Intermediate vs. favorable | 0.846 | 1.122(0.350,3.596) |
| Poor vs. favorable | 0.672 | 1.228(0.474,3.184) |
| Gene mutation | ||
| NPM1 | 0.898 | 0.951(0.441,2.050) |
| FLT3ITD | 0.414 | 1.360(0.650,2.848) |
| DNMT3a | 0.089 | 2.035(0.896,4.620) |
| IDH1 | 0.809 | 1.165(0.337,4.022) |
| IDH2 | 0.327 | 0.364(0.048,2.745) |
| Treatment protocols | ||
| IA vs.DA | 0.111 | 0.372(0.111,1.254) |
| HAA vs.DA | 0.390 | 0.366(0.037,3.613) |
HR hazard ratio;CI confidence interval;
*Multivariate analysis were performed by Cox proportional hazards models with the backward likehood stepwise procedures.